Search Results 911-920 of 18600 for Relapse
... relapse based on the presence of pre-transplant risk factors. Participation eligibility. Participant eligibility includes age, gender, type and stage of ...
Root Cause of Multiple Myeloma Relapse Revealed. Dana Sparks. September 18, 2013. Cancer. Mayo Clinic Receives $8.8 Million Federal Grant for Metabolomics ...
... relapsed or refractory following at least 1 line of prior therapy * Part 2 Cohort J: CLL/SLL participants whose disease relapsed or was refractory to prior ...
Root Cause of Multiple Myeloma Relapse Revealed. Related Articles. Mayo Clinic Minute: How liver transplant is transforming care for patients with advanced ...
... relapse, disability can worsen. It affects up to 10 in 100,000 people. Currently, the immunosuppressive therapies used to prevent neuromyelitis optica relapses ...
Daratumumab-lenalidomide and daratumumab-pomalidomide in relapsed lenalidomide-exposed or refractory multiple myeloma. Anticancer Drugs. 2024 Jan 1; 35 (1): ...
NL-201 in Patients With Relapsed or Refractory Cancer. Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz. The purpose of this study is to ...
Mayo Clinic to offer CAR T-cell therapy for relapsed non-Hodgkin lymphoma featured. Cancer. Mayo Clinic to offer CAR T-cell therapy for relapsed non-Hodgkin ...
The purpose of this study is to assess the safety and tolerability of escalating intratumoral doses of mRNA-2752 in participants with relapsed/refractory solid ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your gift to celebrate this day advances our doctors’ lifesaving work.